Results 271 to 280 of about 1,988,593 (307)

Allografting for chronic myeloid leukemia

Current Opinion in Hematology, 1997
Allogeneic stem cell transplantation is the only curative therapy for chronic myeloid leukemia. There have been several recent advances in this field. Early data suggest that blood-derived stem cells are an effective substitute for bone marrow. Allografting can be performed using progenitor cells from other family members, unrelated donors, and ...
D G, Savage, J M, Goldman
openaire   +2 more sources

Chronic Myeloid Leukemia

JAMA
ImportanceChronic myeloid leukemia (CML) has an annual incidence of 2 cases per 100 000 people and is newly diagnosed in approximately 9300 individuals per year in the US. Approximately 150 000 people in the US and 5 million worldwide have CML.ObservationsChronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the ...
Elias, Jabbour, Hagop, Kantarjian
openaire   +2 more sources

Splenectomy in Chronic Myeloid Leukemia

Annals of Internal Medicine, 1978
We review splenectomy in chronic myeloid leukemia, emphasizing recent studies that have evaluated early splenectomy during the chronic phase of the disease. Despite current interest in splenectomy in chronic myeloid leukemia, uncontrolled clinical trials to date suggest that the operation during the early phase neither delays the onset of blastic ...
D J, Wolf, R T, Silver, M, Coleman
openaire   +2 more sources

Autografting in chronic myeloid leukemia

Seminars in Hematology, 2003
Autografting (or autologous stem cell transplant [ASCT]) followed by "rescue" with Philadelphia chromosome (Ph)-negative hematopoietic progenitor cells (HPC) remains a good procedure to guarantee prolonged survival for patients mobilized and autografted soon after diagnosis.
Angelo M, Carella, Germana, Beltrami, Maria T, Corsetti   +2 more
openaire   +2 more sources

Treatment of Chronic Myeloid Leukemia

Annual Review of Medicine, 1980
Most known chemotherapy agents, used singly, may induce remission of CML. Those that best alleviate symptoms (anemia, splenomegaly, etc) do not change either the Ph' chromosome anomaly in the hemopoietic cells nor the median delay of 3--4 years before fatal blastic transformation.
openaire   +2 more sources

Ponatinib for Chronic Myeloid Leukemia

New England Journal of Medicine, 2012
The treatment of patients with chronic myeloid leukemia (CML) must be ranked as one of the great medical success stories of the past 30 years. The demonstration that the Philadelphia (Ph) chromosome carries a fusion gene formed by the juxtaposition of BCR and ABL genetic sequences focused attention on the possibility that the tyrosine kinase activity ...
openaire   +2 more sources

Immunotherapy of Chronic Myeloid Leukemia

2006
Imatinib has become standard therapy for all phases of chronic myeloid leukemia (CML). However, data generated by monitoring several thousands of patients worldwide suggest that although imatinib is highly active against the differentiated mass of CML cells, it probably fails to eradicate all residual leukemia cells, even in the best responders.
BOCCHIA M., LAURIA F.
openaire   +3 more sources

Chronic myeloid leukemia

The American Journal of Medicine, 1986
R T, Silver, R P, Gale
openaire   +2 more sources

Chronic Myeloid Leukemia

Emerging Cancer Therapeutics, 2010
Elias Jabbour, Hagop M. Kantarjian, Jorge E. Cortés   +2 more
openaire   +1 more source

Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future

Cells, 2021
Valentina Rene' Minciacchi, Daniela S Krause, Rahul Kumar   +2 more
exaly